News
The 17 members of a federal vaccine advisory committee, who were ousted last week, argued their abrupt dismissal has "left the U.S. vaccine program critically weakened." The group, speaking ...
The incidence of RSV across 5 respiratory virus seasons was substantial among adult patients with high-risk underlying conditions.
Dr. Lbiati's appointment signals a new chapter for Hepion-one focused on strategic renewal, value creation, and diagnostic ...
Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB T6G 2R3, Canada Department of Chemistry, University of Alberta, Edmonton, Alberta T6G 2G2, Canada Department of ...
Albertans who want to continue to protect themselves from the COVID-19 virus will have to pay out of pocket for it starting in the fall of 2025, the province announced on Friday.
Cleveland health officials are warning residents after a 250% spike in COVID-19 viral levels was found in city wastewater.
Cleveland Department of Public Health officials are warning of a “strong likelihood of increased community spread in the ...
The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include individuals 18-59 years of age who are at increased risk for severe illness from ...
RESVIA is now authorized for use in adults aged 18–59 years with an increased risk of respiratory syncytial virus-related ...
The FDA has approved Enflonsia (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in neonates and ...
The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...
3d
Medindia on MSNFDA Approves ENFLONSIA to Shield Infants From RSVIn a major boost for infant health, the U.S. Food and Drug Administration (FDA) has approved ENFLONSIA (clesrovimab-cfor) , a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results